Randomized, Controlled, Double-Blind Proof of Concept Trial Assessing the Efficacy and Safety of BioBlock® Intranasally Administered Virus-Neutralizing Bovine Colostrum Nasal Spray in Preventing of COVID-19 Infection in Healthy Volunteer Individuals.
This is a randomized (1: 1) parallel study of a double-blind cluster of proof of concept. The randomization unit is healthy volunteers who have no symptoms of COVID-19 at baseline and have not been infected with SARS-CoV-2 for the past 90 days. Selected subjects are be randomly assigned to either an experimental group (subjects using BioBlock® Antiviral Nasal Spray immediately after waking up in the morning and once every 4 hours thereafter for 28 days) or a control group (subjects using placebo immediately after waking up in the morning and once every 4 hours thereafter and so within 28 days).
For both study groups, a rapid COVID-19 antigen test is scheduled twice weekly or for 4 consecutive weeks if symptoms of COVID-19 infection occur.
Cases of side effects are recorded during the study.
Indicative duration of the study is March 2022-August 2022